Navigation Links
42nd Mid-year Topical Meeting of the Health Physics Society
Date:1/22/2009

McLean, VA, January 22, 2009 What would be your response to a radiological incident? How will your State and the Feds respond? Who would or can take care of us? How do we even know if we are exposed to radiation?

These and other questions will be addressed at the 42nd Midyear Topical Meeting of the Health Physics Society (HPS), which will take place January 31-Feb 3, 2009 in San Antonio, Texas at the Henry B. Gonzales Convention Center. The topic is "Recent Advances in Planning and Response to Radiation Emergencies." Approximately 400 attendees are expected, with over 110 presentations throughout the three days.

MEETING HIGHLIGHTS

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/18/2015)... 2015 As mobile payments become more ... wallets and apps continue to be introduced into the market ... mobile payment industry in focus today are:  NXT-ID, Inc. (NASDAQ: ... BABA ), Apple Inc. (NASDAQ: AAPL ), ... (NASDAQ: FB ) NXT-ID, Inc. (NASDAQ: ...
(Date:3/12/2015)... , March 12, 2015 IriTech, a ... a member of the Texas Instruments Design Network, announced ... has demonstrated its IriShield USB MK2120U device during ... facility for pension distribution. The iris ... to be marketed in India ...
(Date:3/11/2015)... --  The Sync Project™ today announced the ... harness music to improve health. The platform maps ... of physiology, enabling the study of the therapeutic ... It is designed for medical and health research, ... and accelerate the discovery of the clinical applications ...
Breaking Biology News(10 mins):Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 2Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 6Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 3Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 3
... combine forces? Individuals with chronic myeloid ... as imatinib (Gleevec), which targets the protein known to ... BCR-ABL mutants emerge that are resistant to the effects ... as dasatinib (SPRYCEL), which targets BCR-ABL in a different ...
... A detailed map that pinpoints the location of every ... evolutionary steps needed to create the molecules modern version, ... at Chapel Hill and the University of Oregon. ... the proteins and other molecules necessary for life have ...
... having kids to help raise the offspring of others ... reproduce, but many African starlings have adopted this strategy ... habitats, according to a new study by University of ... the Aug. 21 issue of the journal Current Biology. ...
Cached Biology News:JCI table of contents: Aug. 16, 2007 2JCI table of contents: Aug. 16, 2007 3JCI table of contents: Aug. 16, 2007 4JCI table of contents: Aug. 16, 2007 5JCI table of contents: Aug. 16, 2007 6JCI table of contents: Aug. 16, 2007 7Structure of 450 million year old protein reveals evolution's steps 2Savanna habitat drives birds, and perhaps others, to cooperative breeding 2Savanna habitat drives birds, and perhaps others, to cooperative breeding 3Savanna habitat drives birds, and perhaps others, to cooperative breeding 4
(Date:3/30/2015)... March 30, 2015  Naldemedine, an investigational peripherally ... Shionogi & Co., Ltd., met its primary and ... I) for the treatment of opioid-induced constipation (OIC) ... opioid therapy. Study results showed that naldemedine (0.2 ... the frequency of spontaneous bowel movement (SBM) compared ...
(Date:3/29/2015)... , March 29, 2015 Caris ... important study data showing the presence of ... gynecologic cancer samples. Using Caris Molecular Intelligence®, ... researchers identified expression of programmed cell death ... of histology while its ligand (PD-L1) expression ...
(Date:3/27/2015)... , March 27, 2015  Neogen Corporation (NASDAQ: ... adopted a prearranged trading plan in accordance with Securities ... Chairman and CEO of Neogen Corporation, is a minority ... Corporation common stock. Herbert does not have ... appropriate. The filing is only for a portion of ...
(Date:3/27/2015)... Md. , March 27, 2015  CASI Pharmaceuticals, ... to the acquisition, development and commercialization of innovative therapeutics ... global market with a commercial focus on ... three and 12 months ended December 31, 2014.  ... ($1.6 million), or ($0.05) per share, for the three ...
Breaking Biology Technology:Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 2Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 3Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 4Neogen CEO adopts 10b5-1 Trading Plan 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 3CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 4CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 5CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 6
... Investment Conference on... -- HARBIN, China, Sept. 7 /PRNewswire-Asia-FirstCall/ -- ... ... --> ... { var s = ,; var first_result; // Results are keyed by longUrl, so we need ...
... Calif., Sept. 7 / PRNewswire/ -- Transdel ... announced that Transdel management will present a company overview at ... York City on Monday, September 13, 2010 at 4:05 p.m. ... webcast via the Internet by visiting the Investor Relations section ...
... Exclusive Partnership Agreements for Immunotherapy Tablets in Japan -- ANTONY, France, September 6, 2010 ... ... --> ... var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab ...
Cached Biology Technology:Weikang Bio-Technology to Present at Rodman and Renshaw's Annual Global Investment Conference on September 14th 2010 2Weikang Bio-Technology to Present at Rodman and Renshaw's Annual Global Investment Conference on September 14th 2010 3Weikang Bio-Technology to Present at Rodman and Renshaw's Annual Global Investment Conference on September 14th 2010 4Weikang Bio-Technology to Present at Rodman and Renshaw's Annual Global Investment Conference on September 14th 2010 5Weikang Bio-Technology to Present at Rodman and Renshaw's Annual Global Investment Conference on September 14th 2010 6Weikang Bio-Technology to Present at Rodman and Renshaw's Annual Global Investment Conference on September 14th 2010 7Transdel Pharmaceuticals to Present at Rodman & Renshaw 12th Annual Healthcare Conference 2Transdel Pharmaceuticals to Present at Rodman & Renshaw 12th Annual Healthcare Conference 3Stallergenes and Shionogi Sign Exclusive Partnership Agreements for Immunotherapy Tablets in Japan 2Stallergenes and Shionogi Sign Exclusive Partnership Agreements for Immunotherapy Tablets in Japan 3Stallergenes and Shionogi Sign Exclusive Partnership Agreements for Immunotherapy Tablets in Japan 4Stallergenes and Shionogi Sign Exclusive Partnership Agreements for Immunotherapy Tablets in Japan 5Stallergenes and Shionogi Sign Exclusive Partnership Agreements for Immunotherapy Tablets in Japan 6Stallergenes and Shionogi Sign Exclusive Partnership Agreements for Immunotherapy Tablets in Japan 7Stallergenes and Shionogi Sign Exclusive Partnership Agreements for Immunotherapy Tablets in Japan 8Stallergenes and Shionogi Sign Exclusive Partnership Agreements for Immunotherapy Tablets in Japan 9
Peptide-affinity Purified Polyclonal Antibody to ICEBERG Peptide with sequence EEDPQLASKMGLH, from C Terminus of the protein sequence according to NP_067546...
EDG-6 Lysate Source: Cell Lysate Application: Western Blotting Control Form: IgG...
3T3 cells (RSV-transformed) Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
Madin-Darby bovine kidney (MDBK) cells Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
Biology Products: